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Germline mutations are a driving force behind genome evolution and genetic disease. We 
investigated genome-wide mutation rates and spectra in multi-sibling families. Mutation rate 
increased with paternal age in all families, but the number of additional mutations per year 
differed more than two-fold between families. Meta-analysis of 6,570 mutations showed that 
germline methylation influences mutation rates. In contrast to somatic mutations, we found 
remarkable consistency of germline mutation spectra between the sexes and at different paternal 
ages.  3.8% of mutations were mosaic in the parental germline, resulting in 1.3% of mutations 
being shared between siblings. The number of these shared mutations varied significantly 
between families. Our data suggest that the mutation rate per cell division is higher during both 
early embryogenesis and differentiation of primordial germ cells, but is reduced substantially 
during post-pubertal spermatogenesis. These findings have important consequences for the 
recurrence risks of disorders caused by de novo mutations. 
Introduction 
Mutations have manifold consequences, from driving evolution to causing disease. DNA damage can 
have exogenous causes such as ionizing radiation and mutagenic chemicals or endogenous causes 
such as oxidative respiration and errors in DNA replication1,2. Both endogenous and exogenous 
damage are restored by DNA repair pathways, which are highly conserved in mammals2. However, 
damage repair pathways are not perfect and de novo mutations (DNMs) occur in every generation. 
Knowledge of the rates and mechanisms by which germline mutations arise has diverse applications, 
from empowering the discovery of the genetic causes of rare disorders3, to dating critical periods in 
human evolution4. Based on whole-genome sequencing studies of trios the average generational 
mutation rate of single base substitutions in humans has been estimated5-9 to be  ~1-1.5×10-8. 
In 1947, Haldane noted that the mutation rate of the hemophilia gene is significantly higher in men 
than in women10. Recent genome sequencing studies confirmed Haldane’s observation that the male 
germline is more mutagenic5-8,11. On average, each additional year in the father’s age at conception 
results in ~2 additional DNMs in the child6. Correspondingly, the risk of dominant genetic disorders 
in the child increases with increasing paternal age12,13. The most likely cause of the paternal age 
effect is the increasing number of cell divisions in the male germline14. While oocytes are produced 
early in a woman’s life and have a fixed number of genome replications, spermatogenic stem cells 
undergo continuous genome replication throughout a man’s life. It has been estimated that the male 
germline experiences 160 genome replications in a 20 year old male, rising to 610 genome 
replications in a 40 year old male15. 
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Mutation rate depends on local nucleotide context. Moreover, studies of somatic mutations in 
cancer have shown that the observed mutation spectra can be decomposed into different 
‘mutational signatures’ that reflect particular cellular contexts of exogenous and endogenous 
mutagen exposure and the efficiency of different DNA repair pathways16.  
The germline comprises a lineage of different cellular contexts, from the zygote to the gamete17 
(Supplementary Figure 1). Post-zygotic mutations can potentially lead to germline mosaicism. 
Observing apparent DNMs shared between siblings – predominantly in studies of dominant 
disorders – has provided direct evidence for germline mosaicism18. While recent studies have 
determined the average germline mutation rate and estimated the average paternal age effect, a 
deeper understanding of germline mutational rates, spectra and their underlying mutational 
processes remains elusive. For example, it is not known whether mutation spectra differ between 
paternal and maternal germlines, nor whether mutation rates and spectra vary significantly between 
families, or whether different stages of the cellular lineage between zygote and gamete differ in 
their mutation rates and spectra. 
Here, we investigated human germline mutations within and between multi-sibling families. This 
allowed us to compare mutation rates and spectra between families and to detect instances of post-
zygotic mosaicism. We also investigated mutational processes and spectra more broadly by 
combining our data with previously published datasets. 
Results 
Family-specific paternal age effects 
We sequenced the genomes of three multi-sibling families (Figure 1). We discovered and validated 
768 DNMs across the three families, with an average of 64 per child (range 43–84, Supplementary 
Table 1). When taking into account genomic regions inaccessible to our analyses (Methods), the 
average number of mutations per individual increases to 76.9. This adjusted number of mutations is 
equivalent to an average mutation rate of 1.28×10−8 (95% confidence interval 1.13–1.43×10−8) at a 
mean paternal age of 29.8 years. In the following analyses, we used the adjusted number of 
mutations. 
We determined the parental origin of 399 DNMs, 311 of which (78%) were of paternal origin (Figure 
1). Our data confirm the paternal age effect. Taking all families together, the number of DNMs 
increases with the fathers’ age by 2.87 per year (95% confidence interval 2.11–3.64). In all three 
families, there is a 12–13 year gap between the youngest and oldest siblings, which enabled us to 
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estimate the parental age effect for each family separately. The correlation between paternal age 
and the number of DNMs in the child was even stronger when each family is considered separately 
(Figure 2). The parental age effect for family 244, 603, and 569 is 1.46 (95% confidence interval 
1.15–1.78), 3.27 (CI 2.07–4.47), and 3.65 (CI 1.52–5.77) mutations per year, respectively. Overall, a 
model that takes both paternal age and family into account performs significantly better in 
predicting the number of mutations in the offspring than a model that only considers paternal age (p 
= 0.020, Analysis of Variance). 
Germline mosaicism in parents 
Mutations that occur during early development can lead to mosaicism in germline and/or somatic 
tissues. Germline mosaic mutations in parents could be passed on to more than one child. We used 
two orthogonal approaches to identify potential parental germline mosaic DNMs in our multi-sibling 
family sequencing data, by deeply sequencing every validated DNM in every individual in all three 
pedigrees to a mean depth of 567X per individual (Methods). 
First, we identified 10 validated DNMs that are shared between at least two siblings in the same 
family, which are clearly not constitutively heterozygous in either parent (alternate allele fraction 
<10%). Based on this, the probability of any germline mutation being shared between two siblings is 
1.3% (Supplementary Table 2).  
Second, by identifying sites with a significant excess of alternative (ALT) reads in the DNA from a 
single parent (Methods), we distinguished sites among the validated DNMs that were potentially 
mosaic at low levels in parental blood (Figure 3B, Table 1, Supplementary Figure 2). This approach 
identifies germline mutations mosaic in at least one parental somatic tissue, and thus most likely 
occurred during early embryonic development of the parent, prior to the separation and 
proliferation of the germline and the soma, and consequently are mosaic in both tissues. We 
attempted further experimental validation of the candidate mosaic sites using orthogonal 
amplification and sequencing technologies (Methods). Taking these independent experiments 
together, we identified 25 DNMs with excess parental ALTs, ranging from 0.6% to 10% of the reads, 
with a median of 3%. We modeled our statistical power to detect parental somatic mosaicism 
(Figure 3A) and conclude that we have ~80% power to detect a mosaic variant present in 1% of 
parental blood cells and ~90% power to detect a variant in 2% of parental blood cells. 
Six of the ten DNMs shared among siblings also exhibited parental somatic mosaicism, which is a 
significant enrichment (p=4.6e-7, Fishers Exact Test). Four DNMs were shared among siblings 
without excessive ALTs in parental blood. Hence they either occurred after the separation of 
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germline and soma, or had parental somatic mosaicism below detectable levels. In total, 29 of 
validated DNMs have evidence of parental germline mosaicism (Table 1). Correcting for our 
incomplete power to detect mosaic mutations (Figure 3A), suggests that 4.2% of germline mutations 
may be may be mosaic in >1% of parental blood cells (Methods). 
64% (16/25) of the parental mosaic DNMs were maternal in origin. This is compatible with a 1:1 ratio 
of paternal and maternal somatic mosaicism but represents a significantly different ratio of parental 
origins compared to paternal bias observed in all 768 DNMs (p=7.7e-6, binomial test). There is not 
likely due to differential sequencing-coverage between mothers and fathers (Supplementary Figure 
3). 
Germline mutational spectra 
We compiled a catalogue of 6,570 high confidence DNMs from 109 trios based on six different 
sources, including the families we sequenced for this project (Supplementary Table 3). All DNMs 
were called from whole-genome sequencing data. For 10% of the mutations, data on parental origin 
were available. 
We used this catalogue to evaluate evidence for distinct germline mutational processes. Low 
resolution mutational spectra, which we define as the relative frequency of the six possible point 
mutations confirm the expected preponderance of transitions over transversions (Figure 4A). There 
was no significant difference between the spectra of maternal and paternal mutations (p = 0.19, Chi-
squared test; Figure 4B). Even though there is a significant difference in the magnitude of the 
paternal age effect between the three families, there is no significant difference between the 
mutational spectra of the three families (p = 0.925, Chi-squared test, nor between the spectra of 
DNMs of children born to young and old fathers (p = 0.83, Chi-squared test; Figure 4C). 
As an independent assessment of potential differences in maternal and paternal mutation spectra, 
we contrasted variants identified on chrX and chrY in a genome-wide sequencing dataset based on 
2,453 individuals from the UK10K project. All variation on chrY arose in the male germline, whereas 
variation on chrX is generated in both the maternal and paternal germline. We observed that only 
rare variants faithfully recapitulate the mutation spectra observed in de novo mutations19, as the 
ratio of C:G>T:A and T:A>C:G transitions decreases dramatically with increasing derived allele 
frequency, most likely because of biased gene conversion20 (Supplementary Figure 4). We did not 
observe any statistically significant difference (p = 0.10, Chi-squared test) in chrX and chrY mutation 
spectra (number of variants = 3,217) after accounting for base composition differences between the 
chromosomes (Methods, Supplementary Figure 5). This confirms our observation above that 
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despite the differences in mutation rates, numbers of genome divisions and cellular contexts, the 
mutation spectra in the maternal and paternal germline are very similar. 
To investigate the contribution to germline mutation of 30 previously identified and validated 
mutational signatures operative in somatic lineages leading to cancer16, we characterised higher-
resolution mutational spectra. For this, we calculated the relative frequency of mutations at the 96 
triplets defined by the mutated base and its flanking base on either side (Figure 5A). The spectrum 
observed for germline mutations clearly recapitulates the known higher mutability of CpG 
dinucleotides. 
We evaluated if any combination of the 30 previously identified signatures16 is sufficient to explain 
the observed pattern of germline mutations (Figure 5B). Two of the mutational signatures, 
previously termed Signatures 1 (25% of DNMs) and 5 (75% of DNMs), explain the majority of the 
observed mutational pattern (Pearson correlation = 0.98; Figure 5C). Including any additional 
mutational signatures did not significantly improve this correlation. Signature 1 is characterised by 
C:G>T:A mutations at CpG dinucleotides, while Signature 5 is predominately characterised by 
T:A>C:G mutations (Supplementary Figure 6). These signatures are responsible for the generation of 
the majority of spontaneous pre-neoplastic somatic mutations16, indicating that the mutational 
processes underlying these signatures in somatic cells are also operative in the germline. 
Methylated CpG sites spontaneously deaminate, leading to TpG sites and increasing the number of 
C:G>T:A mutations21. To test whether methylation status in the germline has a detectable impact on 
mutations, we obtained cell-line methylation data for three cell types that had been generated by 
reduced representation bisulfite sequencing as part of the ENCODE project22. In the testis cell-line, 
25.3% of CpG sites had more than 50% of reads methylated (Supplementary Table 4). 13 of those 
sites overlap with DNMs from our catalogue, of which 12 have more than 50% of reads methylated. 
This means that in the testis cell-line, methylated CpG sites are significantly more likely to mutate 
than unmethylated ones (p = 1.71×10-8, Binomial test). All of the 12 DNMs that were methylated in 
the testis are CpG>TpG mutations (Supplementary Table 5). For B-lymphocyte and embryonic stem 
cell-lines, the association between methylation status and mutation is less significant (p = 0.04 and p 
= 2.39×10-6, respectively). 
Discussion 
We sequenced the genomes of three multi-sibling families, identified candidate DNMs and validated 
768 of them by targeted re-sequencing. Both the average genome-wide mutation rate of 1.28×10−8, 
and the ratio of paternal to maternal mutations (3.5) are slightly higher than but compatible with 
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previous estimates6. On average, the number of mutations in the child increased approximately 
linearly by 2.9 additional mutations with each additional year in the parents’ age. The magnitude of 
this effect differed by a factor of >2-fold between families. While our observations corroborate a 
previous study6 that proposed that the major factor influencing the number of mutations in a child 
rate is paternal age, our multi-sibling study design allows detection of more subtle differences 
between families. Given that the increase in mutations with parental age is driven by paternal 
mutations, we suggest that this observation could result from variation between males either in the 
rate of turnover of spermatogenic stem cells, or in the mutation rate per cell division. A recent 
review noted that the strength of the paternal age effect differs between studies23. Whilst this could 
be due to study design or analysis choices, our results highlight a more interesting possibility, namely 
that, due to the families in each study, the paternal age effect actually differed between the studies, 
most of which had a limited sample size. 
We observed no difference in mutation spectra between the maternal and paternal germlines or 
between young and old fathers. The lack of large differences in mutation spectra between the sexes 
is perhaps counter-intuitive, given the different cellular contexts in the maternal and paternal 
germline, including the marked difference in cell divisions and thus the increased potential for 
replication-associated mutations in the paternal germline. Larger catalogues of paternal and 
maternal mutations will be required to identify any subtler differences in germline mutation spectra. 
We have shown that a combination of two previously identified mutational signatures operative in 
somatic cell lineages are sufficient to explain the observed mutational spectrum of germline 
mutations. These two mutational signatures were originally extracted from somatic mutations 
derived from diverse cancer genomes and thus likely reflect mutation processes operative across 
somatic tissues16. This high concordance between the germline and the soma suggests that the 
mutation processes underlying these two signatures are associated with maintenance and 
replication of DNA in all cells. The generality of these two signatures, and their underlying mutation 
processes, across diverse cellular contexts, likely explains our observation of an absence of 
appreciable age- or sex-dependent variation in mutation spectrum. Nonetheless, despite this 
genome-wide concordance across different cellular lineages, our observation of increased mutation 
rate at sites known to be methylated in a testis-derived cell-line revealed that DNA methylation, and 
perhaps other cell-type specific factors, has a finer-grained role to play in influencing the precise 
location of mutations in specific cell-types.  
With regard to the timing of mutations in the cellular lineage of the germline, we have shown that at 
least 3.8% of DNMs are mosaic in at least 1% of parental blood cells. This estimate represents a 
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lower bound on the true proportion of DNMs that are mosaic in parental somatic tissues, as we only 
sampled a single somatic tissue and cannot exclude the possibility of very low level (<1%) mosaicism 
in that tissue. This proportion is compatible with a recent estimate for parental somatic mosaicism 
of copy number variants24. We infer that DNMs that are mosaic in parental soma must have arisen 
early on during embryonic development of the parent (first 8-12 cell divisions 25,26), prior to the 
specification of primordial germ cells (PGCs) and the concomitant separation of the germline from 
the soma. Whereas all DNMs showed a 3.5:1 ratio of paternal to maternal mutations, these early 
mutations were compatible with a 1:1 ratio of paternal and maternal origins, as might be expected 
given the origin of these mutations prior to sexual differentiation of the embryo. 
We note that our observations are not compatible with monophyletic origins of blood and germline, 
but that each tissue must be founded by multiple cells with polyphyletic ancestry. A logical 
consequence is that some mesoderm founder cells are more closely related to primordial germ cells 
within the cellular genealogy of the early embryo than they are to other mesoderm founder cells, 
and vice versa. 
One limitation of our study is not having complete ascertainment of all pre-PGC mutations. 
Mutations that arose in very early post-zygotic divisions may well be present at such high 
frequencies within parental tissues that our analytical workflow for identifying candidate de novo 
mutations fails them on the basis that such sites are much more likely to be inherited variants with a 
biased sampling of alleles.  Moreover, pre-PGC mutations that arose in later cell divisions, only just 
before PGC specification, may be mosaic in parental somatic tissues at such low levels that our deep 
resequencing was unable to identify them. Nonetheless, the 20-fold difference in levels of somatic 
mosaicism that we could detect suggests that we were able to detect pre-PGC mutations across at 
least 4 rounds of early embryonic cell division (24 < 20).  
Using the data we have generated on the paternal age effect and the prevalence of parental somatic 
mosaicism, we can interrogate the mutagenicity of different phases of gametogenesis. By assigning 
mutations to early embryonic cell divisions prior to PGC specification, we can estimate a credible 
range for the mutation rate in early cell divisions in parental germlines. Based on the sharing of pre-
PGC mutations between gametes from the same parent, we can define a maximal and minimal 
number of pre-PGC cell divisions within which the observed pre-PGC mutations must have occurred, 
and from these estimate an upper and lower bound on the mutation rate per cell division. Our data 
suggest that the pre-PGC mutation rate per cell division is in a range of ~0.2 to 0.6 (for a haploid 
genome) in both parental germlines). The paternal age effect that we observed implies that a lower 
mutation rate per cell division of a range of ~0.09 to ~0.17 (~2-4 paternal mutations per year derived 
9 
 
from 23 cell divisions) operates during post-pubertal spermatogenesis. By contrast, oogenesis 
appears to be significantly more mutagenic than post-pubertal spermatogenesis with a mutation 
rate per cell division of ~0.5 to ~0.7 (~10-14 maternal mutations arise during ~20 post-PGC cell 
divisions27). In the paternal germline, we also need to consider an intermediate phase of cell division, 
during the proliferation and differentiation of PGCs to form pre-spermatogonia during prenatal 
development. This phase of spermatogenesis is contemporaneous with oogenesis in females. By 
extrapolating the paternal age effect we can estimate the total number of paternal mutations at 
puberty (averaging across pedigrees and assuming no maternal age effect) to be ~19, and by 
subtracting the number of pre-PGC mutations (~2-6, from ~10 divisions), we can estimate the 
number of paternal mutations that arose during this intermediate phase to be ~13-17. It has been 
estimated that there are ~24 cell divisions during this phase27 giving a range of mutation rate per cell 
division of ~0.5-0.7, very similar to that observed during maternal PGC proliferation and 
differentiation to oogonia. 
From these observations we derive a tentative model of germline mutation rate during 
gametogenesis (Figure 6), with two phases of oogenesis and three phases of spermatogenesis, 
wherein the mutation rate per cell division is higher during early embryogenesis and during PGC 
proliferation and differentiation during later embryogenesis, and reduces ~3-fold during post-
pubertal spermatogenesis.  This model is consistent with prior inferences that the average mutation 
rate per cell division must be higher in the female germline given the relative number of cell 
divisions and the ratio of paternal and maternal mutations, and this could be due to a lower error 
rate per cell division after puberty in males 23. It has previously been suggested that the earliest 
embryonic divisions exhibit elevated mutagenicity with respect to structural variation28. Our data 
suggest that for SNVs, the main step change in mutation rate per cell division may be between 
embryonic and post-pubertal phases of gametogenesis in males, and a similar observation has been 
reported in mice spermatogenesis29. If the model that we have proposed above proves to be correct, 
then it suggests that evolutionary selection may have acted to lower the mutation rate per cell 
division during post-pubertal spermatogenesis, perhaps achieving a selective balance between 
producing sufficient numbers of sperm to maintain fertility, while minimizing the deleterious 
mutation rate.  
It is important to note that the estimated ranges for the mutation rate per cell division presented 
above represent a combination of mutations that arise during genome replication and any 
spontaneous mutations between cell divisions. The time interval between cell divisions differs 
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markedly throughout the different phases of gametogenesis, and so these mutation rate estimates 
do not necessarily reflect the mutagenicity of genome replication in isolation. 
We infer that germline DNMs that are mosaic in parental soma will also be mosaic in the germline, 
indeed we observed that the six parental somatic mosaic DNMs that were shared among siblings 
had significantly higher levels of somatic mosaicism, on average, than the other parental somatic 
mosaic DNMs that were not shared between siblings (p=0.009, Mann-Whitney test). This suggests 
that the extent of somatic mosaicism correlates with the extent of germline mosaicism, and hence 
the probability that a DNM will be observed recurrently among siblings. 
We identified four DNMs that were shared among siblings, and thus are highly likely to be mosaic in 
the parental germline, although we observed no evidence for accompanying somatic mosaicism in 
parental blood. We infer that these mutations may have arisen in early cell divisions post-PGC 
specification and thus mosaicism is restricted to the germline.  
Previous studies of germline mosaicism of sequence variants have been largely limited to case 
studies of sibling recurrence of pathogenic DNMs30-34. Our 1.3% estimate of the average recurrence 
probability is compatible with those empirical studies, but they are not compatible with recent lower 
estimates of recurrence risks derived from theoretical modeling of the cellular genealogy of the 
germline35. We note that these recurrent DNMs between siblings were not randomly distributed 
between families, but were significantly enriched in one pedigree. This suggests that there may also 
be significant variation between families in patterns of germline mosaicism of DNMs. 
These results on germline mosaicism have implications for the genetic counselling of recurrence risks 
for families with children with genetic disorders caused by DNMs 17. While the currently used 
recurrence risk of ~1% is supported by our findings, our data suggest that this represents an average 
across DNMs with very different recurrence risks. While only 1.3% of all DNMs were observed 
recurrently among siblings, this increases to 24% for DNMs that were mosaic in >1% of parental 
blood cells and 50% for DNMs mosaic in >6% of parental blood cells. Our data suggest that deep 
sequencing of parental blood for pathogenic DNMs seen in children should enable meaningful 
stratification of families into a substantial majority with <1% recurrence risks, and a small minority 
with recurrence risks that could be at least an order of magnitude higher. Considerably more data 
will be required to enable more precise quantitative estimates of recurrence risks given an observed 
extent of parental somatic mosaicism. 
Our data also show that in the absence of deep sequencing of parental somatic tissue(s), knowing 
the parental origin of DNM alters the recurrence risk, with maternal mutations likely having a ~3 to 
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4-fold higher recurrence risk, on average, than paternal mutations. As noted previously24, the higher 
probability of germline mosaicism for maternally-derived DNMs results in a higher recurrence risk, 
on average, for DNMs causing X-linked recessive disorders than for autosomal dominant disorders. 
Pedigree based analyses always are limited by the number of offspring available. Deep sequencing of 
single gametes from different individuals36 should enable us to characterise and compare their 
mutation rates and spectra at much higher resolution. This will also mitigate any biases associated 
with the selection inherent during conception and fetal development, although it would still be 
prone to biases caused by mutations that confer enhanced proliferation on progenitors of 
gametes12. Moreover, sequencing progenitors of gametes from different stages of the germline 
would illuminate our current limited understanding of the selective pressures operative throughout 
the genealogy of the germline. 
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Figure Legends 
Figure 1 Pedigrees of sequenced families 
Identifiers and relationship between the individuals in the three families in this study. Individuals 
that were sequenced are symbolised by full circles and squares, other individuals by dotted circles 
and squares. Age of mother and father at the conception of each child and phasing information are 
summarised in the table.  SFHS5165321 was only used for the part of the analysis related to 
mosaicism.  
Figure 2 Paternal age vs. number of de novo mutations 
The number of DNMs has been corrected to take into account genomic regions inaccessible to our 
methods. Red: Family 244. Yellow: Family 569. Blue: Family 603. Gray areas denote the regions 
covered by the 95% confidence interval of the intercept and slope of the linear regression line for 
each separate family. We note that the confidence intervals for families 244 and 603 do not overlap 
for younger fathers. 
Figure 3 Detection of mutations mosaic in parents  
(A) Simulation of detection power for ranges of mosaicism levels in the parents blood using the 
Miseq depth of coverage for all the de novo mutations (n=768). For mean validation coverage (Miseq 
platform) of 567X in the parents, we have >0.94 power to detect mosaicism of 2% and higher in the 
parents blood. (B) Comparison of parental Alt ratios between de novo mutations vs. germline mosaic 
sites. M is mosaic sites with significant excess of alt in the mother’s blood, P is the sites with 
significant excess of alt in the father’s blood, S is corresponding to the sites that are shared between 
the siblings but we could not detect any excess of alt allele in the either of the parents blood. SM/SP 
refer to the mosaic sites that are shared between the siblings and we have detected significant 
excess of alt in the mother’s blood (SM presented in pink dots) or father’s blood (SP shown in dark 
blue dot).  
Figure 4 Mutational spectra 
(A) Frequency of all mutation types in the catalogue of 6,570 high confidence DNMs (B) Difference in 
the frequency of maternal and paternal mutations for the subset of DNMs with phasing information 
(n=556) (C) Difference in the frequency of mutations of children fathers younger and older than 30 
years (n=680). Error bars represent 95% confidence intervals. 
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Figure 5 Mutational spectrum and signatures 
(A) High resolution mutational spectrum of de novo mutations. Each of the six possible point 
mutations is subdivided into 16 subclasses based on the 3’ and 5’ nucleotide flanking the mutation. 
We note that C:G>T:A and T:A>C:G transitions are more common. Within those categories, CpG sites 
are particularly frequent (B) Correlation of mutational signatures with observed mutations in 
mutational catalogue, correlation of each of the 30 signatures, with signatures 1 and 5 highlighted in 
orange (C) Combination of all possible pairs of signatures, with the combination of signatures 1 and 
5 shown with an arrow. 
Figure 6 Mutation rate model during gametogenesis  
Comparison of mutation rate between spermatogenesis (blue-box) vs. oogenesis (red-box). ߤ௣ and 
ߤ௠ are mutation rate in paternal and maternal genome in respective order and mutation rate per 
each stage of gametogenesis is denoted by number. Gametogenesis is divided into three stages with 
different ranges of mutation rates. Stage 1: Pre-PGC specification (8-12 cell divisions in both 
maternal and paternal germline) ~0.2-0.6 mutations per haploid genome per cell division and this 
rate is the similar in both maternal and paternal gametogenesis, stage 2: post-PGC specification, in 
maternal germline there are ~20 cell divisions, in paternal germline there are ~24 cell divisions post-
PGC up to puberty, mutation rate is similar at this stage in both sexes, (~0.5-0.7 mutations per 
haploid genome per cell division). Stage 3: post-puberty (only applicable to the paternal germline) 
sperm are continuously produced through the asymmetric division of self-renewing spermatogonial 
stem cells with ~23 cell divisions per year. The mutation rate falls to a range of ~0.09 to 0.17 
mutations per haploid genome per cell division.  This model is tentative and does not yet take all 
possible sources of uncertainty into account. 
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Table Legends 
Table 1 Germline mosaic SNVs 
PacBio validation; N/A: not applicable, F: not validated, U: indicates uncertain sites, Y: indicates sites 
that are validated (Methods), mosaic status: S refers to the site that is shared between the siblings 
but the alternative allele could not be detected in either of the parent’s blood, SM: is the mosaic site 
which is shared between the sibling and the excess alt allele were detected in the mother’s blood, SP 
is the mosaic site that is shared between the siblings and excess of alt allele were detected in the 
father’s blood, M represent the mosaic site which has excess of alt in the mother’s blood but not 
shared between the siblings, P is the mosaic site that excess of alt was detected in the father’s blood 
and it is not shared between the siblings. Family Id indicates which of the three families the mosaic 
site is from: 244, 603, 569. Haplotype: refers to the sites that their parental origin is known through 
the experimental analysis (Methods). 
Table 1 
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Coordinations 
(Chr:Position) 
Mutations 
(Ref>Alt) 
Miseq 
Mother 
(Ref/Alt) 
Miseq 
Father 
(Ref/Alt) 
Variant 
Specific 
Error 
Adjusted p-value for Excess 
Alt 
Mosaicism 
(%) 
*PacBio 
Validation 
Mosaic 
Status 
Family 
ID 
Haplotype 
Maternal Paternal 
2:186300610 C:T>T:C 149/0 153/1 0.0008 1.00E+00 1.00E+00 N/A N/A S 603 N/A
2:193157646 T:G>G:T 426/1 443/0 0.0009 1.00E+00 1.00E+00 N/A N/A S 603 Paternal 
9:2959572 G:T>T:G 378/3 699/6 0.0017 1.00E+00 9.84E-01 N/A N/A S 569 N/A
X:110276581 C:T>T:C 607/1 427/0 0.0017 1.00E+00 1.00E+00 N/A N/A S 569 N/A 
5:109729461 C:A>A:C 38/0 37/3 0.0015 1.00E+00 2.32E-02 7.50% Y SP 569 N/A 
1:230857935 G:C>C:G 252/13 366/1 0.0034 9.16E-09 1.00E+00 4.91% U SM 569 N/A
4:131248301 T:G>G:T 403/14 487/0 0.0004 2.06E-20 1.00E+00 3.36% F SM 569 Maternal 
8:10261976 G:T>T:G 292/17 371/0 0.0026 1.43E-14 1.00E+00 5.50% Y SM 569 Maternal
8:92146874 C:G>C:G 546/22 792/2 0.0005 1.52E-31 1.00E+00 3.87% Y SM 569 N/A 
16:60784060 A:G>G:A 278/12 371/0 0.0007 6.32E-15 1.00E+00 4.14% Y SM 569 N/A 
1:47735584 A:G>G:A 574/19 329/0 0.0007 1.94E-22 1.00E+00 3.20% Y M 244 Maternal
2:170651456 C:A>A:C 391/24 388/3 0.0028 1.07E-20 1.00E+00 5.78% Y M 603 Maternal 
2:170651804 A:G>G:A 966/51 986/3 0.0013 3.55E-59 1.00E+00 5.01% Y M 603 Maternal 
2:191908075 A:G>G:A 445/13 599/1 0.0010 2.38E-12 1.00E+00 2.84% Y M 569 Maternal
2:213698262 C:T>T:C 888/27 917/10 0.0020 1.35E-19 1.71E-02 2.95% Y M 603 Maternal 
2:225499135 G:A>A:G 751/11 715/0 0.0003 2.77E-12 1.00E+00 1.44% Y M 603 Maternal
3:98029130 G:A>A:G 981/28 934/1 0.0015 6.39E-23 1.00E+00 2.78% Y M 603 Maternal 
8:113112993 T:C>C:T 463/10 727/0 0.0004 9.81E-12 1.00E+00 2.11% Y M 569 N/A 
13:75697455 C:T>T:C 1004/34 1011/3 0.0009 1.64E-37 1.00E+00 3.28% Y M 603 Paternal
16:65940897 A:G>G:A 1140/33 1168/0 0.0013 4.22E-30 1.00E+00 2.81% Y M 603 Maternal 
X:17047163 G:A>A:G 216/3 119/3 0.0005 1.65E-01 1.00E+00 1.37% Y M 603 N/A
2:32093200 C:G>C:G 1033/1 1060/7 0.0002 1.00E+00 4.98E-06 0.66% Y P 603 N/A 
2:37841931 A:T>T:A 721/0 596/68 0.0003 1.00E+00 2.29E-139 10.24% F P 603 N/A 
3:133108055 A:G>G:A 860/0 869/7 0.0010 1.00E+00 2.67E-02 0.80% U P 603 Paternal
4:86375051 C:T>T:C 1004/1 938/6 0.0004 1.00E+00 1.87E-03 0.64% U P 603 N/A 
5:146765532 C:T>T:C 1011/4 1041/6 0.0002 9.09E-02 2.17E-04 0.57% U P 603 N/A 
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9:126471014 T:G>G:T 920/2 903/6 0.0003 1.00E+00 1.16E-04 0.66% U P 603 Paternal
12:8090871 G:T>T:G 1138/5 1083/46 0.0004 1.27E-01 4.90E-70 4.07% Y P 603 Paternal 
14:89561953 C:G>C:G 682/0 632/4 0.0002 1.00E+00 4.83E-03 0.63% U P 603 Paternal
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Online methods 
We	conducted	a	study	of	genome-wide	germline	mutations	by	sequencing	the	genomes	of	three	
healthy	families	who	participated	in	the	Scottish	Family	Health	Study	(SFHS).	Informed	consent	
was	obtained	from	all	participants.	The	families	were	selected	based	on	genomic	DNA	quality,	
the	number	of	children,	and	the	age	gap	between	the	oldest	and	youngest	sibling.	
De novo mutation discovery 
For	each	of	the	three	families,	the	two	parents	and	children	were	sequenced	to	24.7×	coverage	
on	average.	In	one	of	the	families	(Family	569),	a	child	of	one	of	the	proband	was	also	
sequenced.	We	used	the	DeNovoGear	software1	to	identify	49,893	candidate	DNMs	in	the	
children.	We	identified	likely	false	positives	as	those	sites	that	overlapped	low	complexity	
regions2,	which	we	defined	as	segmental	duplications	or	simple	repeats.	Further,	we	removed	
sites	that	had	more	than	5%	of	reads	supporting	the	alternative	allele	in	either	of	the	parents.	
To	avoid	regions	with	a	large	number	of	misaligned	reads,	we	also	removed	sites	whose	depth	
was	in	the	top	0.01%	quantile	in	terms	of	read	depth.	For	this,	we	assumed	read	depth	to	be	
Poisson-distributed,	with	the	lambda	parameter	of	the	Poisson	distribution	being	equal	to	the	
mean	read	depth	of	the	genome.	Taken	together,	these	filters	resulted	in	4,881	candidate	sites.	
For	validation,	we	designed	Agilent	SureSelect	probes	around	the	sites	that	passed	filtering	and	
resequenced	the	resulting	pulldown	library	using	Illumina	to	139×	coverage	on	average	(range:	
88-191).	We	designed	baits	to	cover	a	200bp	window	around	the	candidate	sites.	The	bait	
design	succeeded	for	4,141	sites.	To	analyse	the	validation	data,	we	classified	each	putative	
DNM	into	one	of	three	categories:	Germline	DNM,	inherited	variant	or	false	positive	and	
evaluated	the	likelihood	of	the	data	under	each	model.	The	three	models	are	defined	below.	In	
addition,	37	of	the	DNMs	were	removed	following	manual	inspection	in	the	IGV	genome	
browser.	
Model 1: Germline DNM.	We	defined	the	likelihood	of	the	data	under	the	DNM	model	as:	
ܮܮ. ܦܰܯ = ܲ݋݅ݏ(݉௠,்݉ ∗ 	݁) + ܲ݋݅ݏ(݀௠, ்݀ ∗ ݁) + ܤ݅݊(ܿ௠, ்ܿ ∗ ݁, 0.5) 
mm, dm,	and	cm	are	the	number	of	reads	supporting	the	mutant	allele	(mostly	the	alternative	
allele)	in	the	mother,	the	father	and	the	child,	respectively.	mT,	dT,	and	cT	are	the	total	number	
of	reads	in	the	mother,	the	father	and	the	child,	respectively.	e is	the	sequencing	error	rate.	
Model 2: Inherited variant.	The	likelihood	that	the	variant	is	inherited	is	defined	as:	
ܮܮ. ܫ = max(ܮܮ. ܫܨܯ, ܮܮ. ܫܨܦ, ܮܮ. ܫܨܯܦ) 
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LL.IFM,	LL.IFD,	and	LL.IFMD	refer	to	the	likelihood	that	the	variant	is	maternally	inherited,	
paternally	inherited,	or	inherited	from	both	parents:	
ܮܮ. ܫܨܯ = ܤ݅݊(݉௠,்݉, 0.5) + ܲ݋݅ݏ(݀௠, ்݀ ∗ ݁) + 	ܤ݅݊(ܿ௠, ்ܿ, 0.5) 
ܮܮ. ܫܨܦ = ܲ݋݅ݏ(݉௠,்݉ ∗ 	݁) + ܤ݅݊(݀௠	, ்݀, 0.5) + 	ܤ݅݊(ܿ௠, ்ܿ, 0.5) 
ܮܮ. ܫܨܯܦ = ܤ݅݊(݉௠,்݉, 0.5) + ܤ݅݊(݀௠, ்݀, 0.5) + 	ܤ݅݊(ܿ௠, ்ܿ, 0.5) 
Model 3: False positive.	
ܮܮ. ܨܲ = ܲ݋݅ݏ(݉௠,்݉ ∗ 	݁) + ܲ݋݅ݏ(݀௠, ்݀ ∗ ݁) + ܲ݋݅ݏ(ܿ௠, ்ܿ ∗ ݁)	 
Correction of the mutation rate 
The	correction	accounts	for	the	part	of	the	genome	that	we	could	not	interrogate	because	of	
insufficient	depth	in	low	complexity	regions,	filtering	procedures	to	exclude	false	positives,	and	
failed	validation.	To	take	into	account	the	different	karyotypes	of	the	male	and	female	genomes,	
the	precise	form	of	the	correction	depend	on	the	sex	of	the	proband:	
ܩ݅ݎ݈ݏ: (1 − ݊݋ܥݒ݃) ∗ (1 − ݂݈݅ݐ݁ݎ݁݀) ∗ (1 − ݊݋ܸ݈ܽ ∗ ݌݌ܣ݆݀ݑݏݐ) ∗ 2 ∗ ݒ݈ܽܦܰܯ ݃݁݊݋݉݁ܮ݁݊݃ݐℎ⁄  
ܤ݋ݕݏ: (1 − ݊݋ܥݒ݃) ∗ (1 − ݂݈݅ݐ݁ݎ݁݀) ∗ (1 − ݊݋ܸ݈ܽ ∗ ݌݌ܣ݆݀ݑݏݐ) ∗ 2
∗ ݒ݈ܽܦܰܯ + ݒ݈ܽܦܰܯܺ ݃݁݊݋݉݁ܮ݁݊݃ݐℎ⁄ 	 
noCvg	is	the	proportion	of	the	genome	that	is	either	N	or	not	covered	at	7x	or	more,	filtered	is	
the	proportion	that	is	a	segmental	duplication	or	a	simple	repeat	(but	not	N	or	low	coverage),	
noVal	is	the	proportion	that	passed	filtering	but	for	which	validation	was	not	possible	(mainly	
due	to	failed	primer	design),	ppAdjust	is	the	proportion	of	non-validatable	calls	that	are	likely	to	
be	true	positives	based	on	their	posterior	probability	as	calculated	by	DeNovoGear,	valDNM	is	
the	number	of	validated	DNMs,	valDNMX	is	the	number	of	validated	DNMs	on	the	X	
chromosome,	and	genomeLength	is	the	length	of	the	human	reference	genome	build	37	without	
the	Y	chromosome,	unmapped	regions,	and	mitochondrial	DNA.	This	correction	assumes	that	
the	mutation	rate	is	similar	in	the	inaccessible	regions	of	the	genome.	On	average,	83.1%	of	the	
genome	was	accessible,	ranging	from	82.1%	to	84.3%	in	different	genomes.		
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Identification of DNMs mosaic in parents 
We	used	two	analytical	methods	to	identify	potential	parental	mosaic	DNMs	in	our	multi-sibling	
family	sequencing	data:	DNMs	shared	among	siblings	and	DNMs	with	excess	alternative	reads	in	
DNA	from	one	parent.	
Method 1: Identification by recurrence in siblings.  
Only	validated	and	therefore	high	confidence	DNMs,	were	used	for	this	analysis.	Validation	
ensured	that	the	DNMs	were	not	constitutively	heterozygous	in	either	parent.	This	method	
involved	the	identification	of	DNMs	that	were	present	in	more	than	one	offspring	from	the	same	
family.		
	
Method 2: Identification by excess of alternative reads in a parent.  
Potential	parental	germline	mosaic	events	were	further	investigated	in	the	768	validated	DNMs	
by	identifying	instances	of	a	significant	excess	of	reads	supporting	the	alternative	allele	in	one	of	
the	parents.	To	improve	our	power	to	detect	candidate	germline	mosaic	sites,	we	performed	an	
additional	Miseq	run	of	the	custom	pull	down	library	we	previously	used	for	validation,	which	
resulted	in	an	average	coverage	of	500X	for	validated	DNMs	(n=768).		The	site-specific	error	
rate	for	each	DNM	was	estimated	by	dividing	the	total	number	of	reads	supporting	the	
alternative	allele	by	the	total	number	of	reads	in	all	non-related	individuals,	from	the	two	
families,	in	which	the	DNM	was	not	discovered.	Hence	the	probability	that	the	observed	number	
of	parental	ALT	alleles	resulted	from	sequencing	error	was	calculated	as	follows:	
݌ெ௔௧௘௥௡௔௟	= ܤ݅݊൫݉௠, 	݉௔௟௧ା௥௘௙, ݁൯ 
݌௉௔௧௘௥௡௔௟ = ܤ݅݊൫ ௔݂௟௧, 	 ௔݂௟௧ା௥௘௙, ݁൯ 
Where	m	and	f are	the	number	of	reads	in	the	mother	and	father	respectively,	alt	and	ref	are	the	
alternate	and	reference	alleles	respectively,	and	e is	the	site-specific	error	rate.	Both	maternal	
and	paternal	p	values	for	each	DNM	were	adjusted	for	multiple	testing	using	the	Bonferroni	
correction.	Sites	that	were	significant	at	an	adjusted	p<	0.05	were	considered	as	mosaic.	In	total,	
24	mosaic	sites	were	validated	using	this	method.	Six	of	these	were	also	discovered	by	the	
sibling	recurrence	method	described	above.	
Estimation of recurrence risk.  
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The	probability	of	an	apparent	DNM	being	shared	between	more	than	one	sibling	in	the	same	
family	was	calculated	as	number	of	instances	of	a	mutation	being	shared	between	two	siblings	
divided	by	the	number	of	pairwise	comparisons	between	two	siblings,	in	all	three	families	
(Supplementary Table 2).		
Validation of DNMs mosaic in parents 
We	carried	out	further	independent	validation	of	40	candidate	parental	mosaic	DNMs	(method 
1 and 2, Supplementary table)	using	PacBio	amplicon	sequencing.		These	40	candidate	mosaic	
DNMs	were	selected	as	follows:		10	DNMs	that	were	shared	between	siblings	(for	six	of	these	
shared	DNMs	we	had	previously	identified	a	significant	parental	excess	of	alt	alleles,	as	
described	above),	and	30	candidate	mosaic	sites	that	had	an	excess	of	alt	alleles	in	a	parent’s	
blood,	with	a	nominal	p	value	<0.05	.	Note	this	set	of	30	candidates	was	based	on	nominal	
significance	rather	than	Bonferroni	corrected	significance	and	so	represents	a	less	stringent	set	
of	candidate	mosaic	DNMs.	
Primers	were	designed	using	Primer	33	in	order	to	generate	amplicons	with	an	average	length	
of	250	bp,	with	the	candidate	mosaic	site	in	the	middle	of	the	amplicon.	For	each	candidate	
mosaic	site,	amplicons	were	prepared	for	the	mosaic	children	and	their	parents,	including	a	
unique	11	bp	sequence	in	the	forward	primer	to	act	as	a	barcode	for	each	individual.	The	
amplicons	were	prepared	using	a	standard	PCR	protocol.	Two	of	the	candidate	mosaic	sites	
(chr2:	37841931,	and	chr4:	131248301)	failed	to	amplify	and	therefore	were	not	included	in	
this	validation	experiment.		
In	total	114	amplicons	were	successfully	prepared	for	the	remaining	38	sites.	Amplicons	were	
pooled	in	equimolar	amounts	and	prepared	for	circular	consensus	sequencing	with	shared	
libraries	on	PacBio	SMRT	cell.			
Following	PacBio	sequencing,	the	filtered	subreads	and	ROI	(reads	of	insert)	were	generated	
using	SMRTAnalysis	(provided	by	Pacific	Biosciences,	Menlo	Park	CA).	The	resulting	fastq	files	
were	demultiplexed	based	on	the	11bp	unique	barcodes	for	each	individual	and	mapped	to	the	
human	reference	genome	GRCh37	(hg19).	Average	sequence	coverage	from	the	PacBio	data	was	
158X	across	the	114	amplicons.	Lastly,	variants	were	called	from	the	resulting	BAM	alignments	
using	samtools4	mpileup,	version1.1.	Each	of	the	candidate	parental	mosaic	DNMs	were	only	
further	analysed	if	we	observed	~50%	ref/alt	in	the	child,	and	hence	their	parental	alt/ref	were	
counted.	We	categorised	sites	with	this	criteria	into:	1-Validated,	comprising	sites	where	we	
observed	alternative	alleles	in	the	relevant	parent,	2-Uncertain,	comprising	sites	where	we	had	
<90%	power	to	detect	the	alternative	alleles	in	the	parents	(PacBio	detection	power	was	
calculated	using	the	mosaicism	level	from	the	Miseq	data),	and	finally	3-Not	validated,	
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comprising	sites	where	we	had>90%	power	to	detect	the	alternative	allele	in	the	mosaic	
parents	but	failed	to	detect	them.		
We	classified	29	of	the	40	candidate	sites	set	as	parentally	mosaic.	Four	mosaic	DNMs	were	
shared	between	the	siblings	in	the	same	family	but	we	could	not	observe	alternative	alleles	in	
either	parent	in	either	validation	dataset	(Miseq	and	PacBio).	16	sites	were	validated	as	mosaics	
where	the	mosaic	parent	was	confirmed	on	both	platforms	(all	of	these	sites	had	significant	p-
value	for	their	Miseq	data	after	the	Bonferroni	correction).	One	additional	site	with	significant	
nominal	p-value	but	not	significant	adjusted	p-value	for	the	Miseq	data	was	confirmed	mosaic	
on	PacBio.	Two	sites	were	confirmed	as	mosaic	based	on	significant	adjusted	p-value	from	the	
Miseq	only,	as	they	failed	the	PacBio	experiment.	Six	sites	were	confirmed	mosaic	based	on	
Miseq	only	(with	significant	adjusted	p-values),	as	their	mosaicism	level	was	below	detection	
power	on	PacBio.	In	the	remaining	11	sites,	despite	having	significant	nominal	p-values,	the	
adjusted	Miseq	p-value	was	not	significant	and	the	PacBio	data	was	inconclusive	(Table 1 and 
Supplementary table).	
In	summary,	we	attempted	further	experimental	validation	of	40	candidate	mosaic	sites	by	
conducting	deep	amplicon	sequencing	(158X	mean	coverage	per	individual)	in	the	child,	
mother,	and	father’s	blood	using	the	PacBio	platform.	This	validation	experiment	confirmed	the	
presence	of	ALT	reads	in	parental	blood-derived	DNA	at	100%	of	DNMs	(N=9)	where	the	PacBio	
data	had	>90%	power	to	detect	the	level	of	mosaicism	observed	in	the	MiSeq	data.	
Furthermore,	we	observed	100%	concordance	(N=14)	between	the	parental-origin	determined	
by	significant	excess	of	ALT	reads	in	maternal	or	paternal	blood	and	that	determined	by	phasing	
the	DNM	onto	a	parental	haplotype.		
	
Correction for mosaic power detection 
In	order	to	estimate	the	number	of	mosaic	sites	that	we	failed	to	detect	due	to	power	
limitations,	we	ran	1000	simulations	across	our	768	validated	de novo	mutations	with	their	
given	coverage	(from	Miseq	sequencing)	for	a	range	of	mosaicism	levels.		We	calculated	the	
number	of	sites	with	>2%	mosaicism	that	we	failed	to	identify.	For	this	we	defined	two	bins	for	
the	mosaic	level	(2%-4%,	>4.0%).	The	average	undetectable	mosaic	sites	were	calculated	as	a	
product	of	number	of	mosaic	sites	and	average	detection	power	for	each	bin.	Hence,	the	number	
of	germline	mosaics	after	power	adjustment	is		~4%	(31/768)	of	validated	de novo	mutations.		
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Parent of origin 
To	study	the	effect	of	parental	age	and	sex	on	germline	mutations	we	determined	the	parental	
origin	for	the	validated	germline	DNM	using	three	approaches.		
Firstly,	we	used	DeNovoGear’s	readpair	algorithm1	to	obtain	parental	phasing	information.	In	
short,	this	algorithm	determines	the	parent	of	origin	if	haplotype	informative	sites	are	present	
in	phase	with	the	mutation	in	the	child	and	in	the	parents.	The	informative	sites	are	those	that	
are	phased	with	respect	to	the	mutation	in	the	child	because	they	are	located	on	the	same	read	
pair.	Furthermore,	the	genotype	of	the	site	must	be	informative	in	the	parents.	Using	this	
method,	we	identified	an	informative	haplotype	for	198	mutations.	
Secondly,	a	child	of	one	of	the	probands	(SFHS5165328	in	Family	569)	was	also	sequenced.	For	
this	proband,	the	parent	of	origin	was	determined	using	informative	variants	in	a	20	kb	window	
around	the	DNM.	If	the	paternal	haplotype	was	transmitted	to	the	proband	and	the	child	also	
carried	the	DNM,	then	the	mutation	was	classified	as	being	of	paternal	origin.	Similarly,	if	the	
child	carrying	the	paternal	haplotype	did	not	have	the	DNM,	then	the	mutation	was	classified	as	
being	of	maternal	origin.	The	same	logic	was	applied	when	the	child	inherited	the	maternal	
haplotype	of	the	proband.	Using	this	method,	we	identified	an	informative	haplotype	for	30	
mutations.	
Thirdly,	we	experimentally	ascertained	the	parental	haplotype	on	which	the	DNM	arose.	
Genomic	DNA	from	the	child	was	diluted	to	single	molecule	concentration	and	then	re-amplified	
across	48	wells	using	Repli-G	Midi	Kit	from	Qiagen.	The	resultant	amplified	DNA,	along	with	
undiluted	genomic	DNA	from	the	child	and	the	parents,	was	then	Sequenom	genotyped	at	the	
putative	DNM	of	interest,	along	with	the	nearest	haplotype	informative	SNP	(heterozygous	in	
the	child,	and	heterozygous	in	one	of	the	parents).	If	genotyping	assays	were	heterozygous	in	
child,	homozygous	in	parents	at	the	putative	DNM	in	the	unamplified	DNA,	and	homozygous	in	
the	single	molecule	amplified	wells,	then	the	raw	genotype	data	from	the	48	amplified	single	
molecules	was	analyzed	in	two	ways.	Firstly,	haplotype	inference	was	obtained	from	examining	
peak	height	correlations	between	the	genotype	calls	for	the	putative	DNM	and	adjacent	
informative	SNP,	and	clustering	of	calls	was	observed	using	an	in-house	script.	Secondly,	
genotype	calls	(or	peak	heights	pertaining	to	genotype	calls)	from	the	same	well	were	counted	
for	each	locus	and	the	haplotype	derived	from	a	likelihood	ratio	test	as	detailed	by	Konfortov	et 
al.5.	
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Mutational catalogue 
We	generated	a	catalogue	of	human	DNMs	based	on	previously	published	high	confidence	
mutations	obtained	by	whole	genome	sequencing	(Supplementary Table 3).	Only	single	
nucleotide	DNMs	were	included.	Where	necessary,	we	used	the	LiftOver	tool	to	convert	
coordinates	from	NCBI	build	36	to	build	37.	
Mutational spectra and signatures 
Mutational	spectra	were	derived	directly	from	the	reference	and	alternative	(or	ancestral	and	
derived)	allele	at	each	variant	site.	The	resulting	spectra	are	composed	of	the	relative	
frequencies	of	the	six	distinguishable	point	mutations	(C:G>T:A,	T:A>C:G,	C:G>A:T,	C:G>G:C,	
T:A>A:T,	T:A>G:T).	Significance	of	the	differences	between	mutational	spectra	was	assessed	by	
comparing	the	number	of	the	six	mutation	types	in	the	two	spectra	by	means	of	a	Chi-squared	
test	(df	=	5).	
Mutational	signatures	were	detected	by	refitting	of	previously	identified	consensus	signatures	
of	mutational	processes6.	All	possible	combinations	of	at	least	seven	mutational	signatures	were	
evaluated	by	minimizing	the	constrained	linear	function:	
minா௫௣௢௦௨௥௘௦೔ஹ଴ ||ܦ݁ܰ݋ݒ݋ܯݑݐܽݐଓ݋݊ݏሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬԦ −	෍൫ܵଓ݃݊ܽݐݑݎ݁పሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬԦ ∗ ܧݔ݌݋ݏݑݎ݁௜൯||	
ே
௜ୀଵ
	
Here,	ܦ݁ܰ݋ݒ݋ܯݑݐܽݐଓ݋݊ݏሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬԦ	and	ܵଓ݃݊ܽݐݑݎ݁పሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬሬԦ	represent	vectors	with	96	components	corresponding	
to	the	six	types	of	single	nucleotide	variants	and	their	immediate	sequencing	context	and	
ܧݔ݌݋ݏݑݎ݁௜	is	a	nonnegative	scalar	reflecting	the	number	of	mutations	contributed	by	this	
signature.	N	reflects	the	number	of	signatures	being	re-fitted	and	all	possible	combinations	of	
consensus	mutational	signatures	for	N	between	1	and	7	were	examined,	resulting	in	2,804,011	
solutions.	Model	selection	framework	based	on	Akaike	information	criterion	was	applied	to	
these	solutions	to	select	the	optimal	decomposition	of	mutational	signatures.	
Diversity and divergence data 
Diversity	data	was	based	on	2,453	individuals	who	were	whole	genome	sequenced	to	6-8×	
depth	as	part	of	the	ALSPAC	and	Twins	UK	cohorts	within	the	UK10K	project.	Ancestral alleles 
were defined by a maximum parsimony approach as those that appeared in most of five ape species 
(human, chimp, gorilla, orang-utan, macaque)7. Processing	of	great	ape	reference	genome	data	is	
described	below.	Single	nucleotide	variants	were	determined	to	be	equivalent	to	one	of	the	six	
mutation	types	according	to	the	identity	of	the	ancestral	and	derived	alleles.		
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Using	an	approach	that	was	identical	to	that	taken	by	others8,	variant	sites	that	were	likely	to	be	
under	selection	because	they	were	located	in	exonic	regions	or	because	they	were	2kb	
upstream	or	downstream	of	genes	were	filtered	and	excluded	from	the	dataset.	To	avoid	biases	
created	by	misalignment	of	sequencing	reads,	we	also	excluded	sites	that	overlapped	simple	
sequence	repeats	or	segmental	duplications.	Where	DNMs	were	compared	to	variants,	they	
were	subjected	to	the	same	filters.		
Divergence	data	was	based	on	multispecies	alignments	of	the	chimpanzee,	gorilla,	orang-utan,	
macaque	and	human	reference	genomes,	as	provided	by	Ensembl	Compara.	Sites	likely	to	be	
under	selection	were	removed	in	the	same	way	as	described	for	the	diversity	dataset.	Sites	that	
were	different	in	humans	compared	to	the	other	great	ape	species	were	defined	as	
substitutions.		
Sex chromosomes 
We	included	only	the	rarest	5%	of	variants	into	this	analysis,	as	the	spectrum	of	those	variants	
most	resembles	that	of	DNMs,	as	we	show	elsewhere	in	this	study.	From	the	resulting	variants,	
we	obtained	raw	mutational	spectra	for	each	chromosome,	as	well	as	mutational	spectra	
corrected	for	chromosomal	nucleotide	composition.	The	correction	for	chromosomal	nucleotide	
composition	was	done	by	counting	the	number	of	each	of	the	four	nucleotides	in	the	
interrogated	regions	of	each	chromosome.	For	each	variant,	we	determined	the	ancestral	and	
the	derived	allele.	For	each	variant	type,	we	then	divided	the	number	of	variants	by	the	number	
of	nucleotides	that	matched	the	ancestral	allele	(Supplementary Figure 5).	
Methylation data 
We	downloaded	ENCODE	methylation	data	from	the	UCSC	server	for	three	cell-lines:	
BC_Testis_N30	(testes	of	a	41-year	old	Asian	donor),	GM12878	(B-lymphocytes	from	a	
European	Caucasian	donor),	and	H1-hESC	(embryonic	stem	cells).	The	methylation	data	had	
been	obtained	by	reduced	representation	bisulfite	sequencing	(RRBS).	For	each	cell-line,	two	
replicates	were	available.	We	only	included	sites	that	were	represented	in	both	replicates.	
There	were	1,151,596	such	sites	in	BC_Testis_N30,	1,048,775	in	GM12878,	and	1,118,911	in	H1-
hESC.	For	each	cell-line,	we	identified	sites	with	more	than	50%	of	reads	were	methylated	in	
both	replicates	combined.	We	also	identified	sites	that	were	present	in	our	DNM	catalogue.	We	
computed	binomial	p	values	as	Bin(q, n, p),	where	q	is	the	number	of	methylated	DNMs,	n	the	
total	number	of	DNMs	for	which	methylation	data	is	available,	and	p	the	proportion	of	sites	that	
are	methylated	in	the	dataset.	
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